The streak is alive: management narrates back-to-back quarters of the same improvement and shows this quarter extended i
The model's full reasoning — Q3 2017 call → NOWe need to determine if management presents the just-reported period as the latest step in an unbroken, still-running sequence of quarter-after-quarter improvement in the same part of the business, with explicit connection to preceding periods. The transcript is for Q3 2017. We need to see if management says something like "another quarter of growth" or "improved again from last quarter" etc. They talk about strong retail, but do they chain quarters? They mention "our third quarter was markedly improved from the depressed earnings we posted a year ago" - that's year-over-year. They talk about "return to double-digit retail growth" - but that's not necessarily sequential. They mention "September was the highest retail month in Polaris history and August was among the top three" - that's monthly, not quarterly. They don't explicitly say "this is the third consecutive quarter of improvement" or similar. They talk about momentum but not a specific streak. They also mention "we are on that journey and making progress" but that's general. They don't connect Q3 to Q2 as an improvement. They do say "our third quarter was markedly improved from the depressed earnings we posted a year ago" - that's year-over-year. They also say "well ahead of expectations" but not sequential. They mention "we are raising our overall sales guidance" but that's forward-looking. They don't say "for the second consecutive quarter" or "another quarter of growth." They do mention "Momentum carried throughout the quarter" but that's within the quarter. So no explicit sequential chaining. Also, they attribute improvement to various factors, but not a streak. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| MFC | Manulife Financial Corporation | Q3 2023 | 2023-11-09 | C+ |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| WRB | W. R. Berkley Corporation | Q1 2022 | 2022-04-26 | B |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| FMS | Fresenius Medical Care AG & Co. KGaA | Q2 2018 | 2018-07-31 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| EPC | Edgewell Personal Care Company | Q3 2017 | 2017-08-08 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
MNKD · Q4 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES The transcript explicitly frames the just-reported quarter as the second consecutive (or second successive) profitable quarter for the endocrine business unit and for the Company overall. Management ties this directly to actual results in the current period (net income of $1 million GAAP and $7 million non-GAAP in Q4) following the prior 2023 quarter, and states they will continue to focus on growing the profitability of the endocrine business unit, which has had a positive contribution for two straight quarters.
CYBR · Q3 2021 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Udi Mokady explicitly frames Q3 as “another amazing quarter” that follows “an incredible second quarter,” using the single word “acceleration” to describe the quarter. He then quantifies the extension with concrete current-period metrics: subscription ARR growth accelerated to 131 % (reaching $139 million), total 38 % ARR growth (reaching $344 million), recurring revenue growth accelerated to 41 % ($89 million), and new logos accelerated to over 230.
MFC · Q3 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Roy Gori explicitly frames core ROE as having been ahead of the 15%+ medium-term target for the second consecutive quarter, while noting a 35% rise in core EPS this quarter (on top of steady year-on-year growth in core earnings over the past three quarters). Colin reinforces the sequential nature by stating that core ROE “increase[d] to 16.8%” this quarter.